Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
All randomized controlled trials (RCTs) of iguratimod for rheumatoid arthritis (RA) to assess its efficacy and safety are included in this paper. The Review Manager software was used for meta-analysis to assess risk bias of the studies included, and GRADE profiler software was used for the evidence...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/310628 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561064438398976 |
|---|---|
| author | Jiangtao Li Hejuan Mao Yan Liang Yanrong Lu Shuo Chen Nanping Yang Guixiu Shi |
| author_facet | Jiangtao Li Hejuan Mao Yan Liang Yanrong Lu Shuo Chen Nanping Yang Guixiu Shi |
| author_sort | Jiangtao Li |
| collection | DOAJ |
| description | All randomized controlled trials (RCTs) of iguratimod for rheumatoid arthritis (RA) to assess its efficacy and safety are included in this paper. The Review Manager software was used for meta-analysis to assess risk bias of the studies included, and GRADE profiler software was used for the evidence quality of the studies included. Four RCTs involving 1407 patients with RA were included. Meta-analyses showed that, after 24-week therapy, ACR20, tender joint count, swollen joint count, rest pain, physician and patient global assessment of disease activity, HAQ score, ESR, and CRP in iguratimod group were better than those in placebo group and that the difference between those of iguratimod group and those of other DMARDs (MTX and SASP) group was not significant. GRADE evidence classification of the studies included was moderate. Iguratimod for RA had few adverse events, and its efficacy and safety were the same as those of MTX and SASP for RA. The results of this systematic review suggest that more high-quality and large-scaled RCTs were needed to determine the efficacy of iguratimod for RA and whether iguratimod is as effective as other DMARDs besides MTX and SASP. |
| format | Article |
| id | doaj-art-9442b365a6c54da299ec113de05167b2 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-9442b365a6c54da299ec113de05167b22025-02-03T01:26:02ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/310628310628Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid ArthritisJiangtao Li0Hejuan Mao1Yan Liang2Yanrong Lu3Shuo Chen4Nanping Yang5Guixiu Shi6West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Otolaryngology, The First People’s Hospital of Yibin, Yibin, Sichuan 644000, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaThe Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen 361003, ChinaAll randomized controlled trials (RCTs) of iguratimod for rheumatoid arthritis (RA) to assess its efficacy and safety are included in this paper. The Review Manager software was used for meta-analysis to assess risk bias of the studies included, and GRADE profiler software was used for the evidence quality of the studies included. Four RCTs involving 1407 patients with RA were included. Meta-analyses showed that, after 24-week therapy, ACR20, tender joint count, swollen joint count, rest pain, physician and patient global assessment of disease activity, HAQ score, ESR, and CRP in iguratimod group were better than those in placebo group and that the difference between those of iguratimod group and those of other DMARDs (MTX and SASP) group was not significant. GRADE evidence classification of the studies included was moderate. Iguratimod for RA had few adverse events, and its efficacy and safety were the same as those of MTX and SASP for RA. The results of this systematic review suggest that more high-quality and large-scaled RCTs were needed to determine the efficacy of iguratimod for RA and whether iguratimod is as effective as other DMARDs besides MTX and SASP.http://dx.doi.org/10.1155/2013/310628 |
| spellingShingle | Jiangtao Li Hejuan Mao Yan Liang Yanrong Lu Shuo Chen Nanping Yang Guixiu Shi Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis Clinical and Developmental Immunology |
| title | Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis |
| title_full | Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis |
| title_fullStr | Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis |
| title_full_unstemmed | Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis |
| title_short | Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis |
| title_sort | efficacy and safety of iguratimod for the treatment of rheumatoid arthritis |
| url | http://dx.doi.org/10.1155/2013/310628 |
| work_keys_str_mv | AT jiangtaoli efficacyandsafetyofiguratimodforthetreatmentofrheumatoidarthritis AT hejuanmao efficacyandsafetyofiguratimodforthetreatmentofrheumatoidarthritis AT yanliang efficacyandsafetyofiguratimodforthetreatmentofrheumatoidarthritis AT yanronglu efficacyandsafetyofiguratimodforthetreatmentofrheumatoidarthritis AT shuochen efficacyandsafetyofiguratimodforthetreatmentofrheumatoidarthritis AT nanpingyang efficacyandsafetyofiguratimodforthetreatmentofrheumatoidarthritis AT guixiushi efficacyandsafetyofiguratimodforthetreatmentofrheumatoidarthritis |